Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) fair value: what the stock is really worth
We calculate from audited financials what Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
59‑month range 7.72 TRY – 23.13 TRY · fair‑value band 3.73 TRY – 6.74 TRY · the 7.72 TRY price screens above the 5.23 TRY fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, rapid antigen test kits, and automated nucleic acid (NA) extraction instruments in Turkey.
Show more
Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S., a biotechnology company, engages in the design, development, and manufacture of real-time PCR kits, nucleic acid extraction kits, rapid antigen test kits, and automated nucleic acid (NA) extraction instruments in Turkey. It offers microbiology, genetic disorder, multiplex panel, drug resistance sequencing, food testing kits, as well as sample collection and transport; and full automation, manual magnetic bead NA extraction, and automated NA extraction instrument kits. The company also provides products for diseases, such as hepatitis, herpes simplex virus, human papillomavirus, COVID-19, respiratory infections, monkeypox, human immunodeficiency virus, west nile virus, meningitis, brucella, crimean-congo hemorrhagic fever, sexually transmitted diseases, epstein-barr virus, tuberculosis, JC and BK polyomaviruses, cytomegalovirus, parvovirus B19, toxoplasmosis, ureaplasma, torque teno virus, factor V leiden mutation, factor II prothrombin mutation, methylenetetrahydrofolate reductase, influenza, and respiratory syncytial virus diseases. In addition, it is involved in installation of robots, developing software; and designing of devices for research of real-time PCR. Anatolia Tani ve Biyoteknoloji Ürünleri Ar-Ge Sanayi Ticaret A.S. was founded in 2010 and is headquartered in Istanbul, Turkey.
Stock analysis
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) currently trades at 7.72 TRY, while our model-based Fair Value estimate is 5.23 TRY, implying the stock looks roughly 47.6% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 3.73 TRY (bear) to 6.74 TRY (bull), the price of 7.72 TRY sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret reported revenue of 740M TRY in FY2025 versus 410M TRY in FY2021, a compound +15.9%/yr. Reported net income was −313M TRY in FY2025.
Key figures
Market cap 2.1B TRY (≈ $42.1M) · P/S ratio 2.61 · EPS (TTM) −1.46 TRY · Dividend yield 13.0% · Net margin −42.3% · Return on equity −16.4% · Return on assets (EBIT) 9.0% · Operating margin 3.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 52% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −32%, ANGEN screens richer than that median.
Fair Value models
Bear 3.73 TRYFair Value 5.23 TRYBull 6.74 TRY
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.33/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.9%
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.6%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
81.2% (2020) → −7.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 351 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score33 · Bottom 25%
Fair Value upside−40% · Below median
Profitability
Return on assets−2% · Below median
Net margin (TTM)−36% · Bottom 25%
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth19% · Top 25%
Dividend yield (TTM)13.0% · Top 25%
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/S (TTM)0.05× · Cheapest 25%
EV/EBITDA2.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 5
FUTURE (revenue growth)96· sector 31
PAST (return on equity)0· sector 8
HEALTH (low debt)95· sector 97
DIVIDEND (yield)0· sector 38
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret Fair Value". https://www.fairvalue-calculator.com/stock/ANGEN
Frequently asked questions
Is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 5.23 TRY versus a price of 7.72 TRY, about −32% upside (overvalued).
What is the fair value of ANGEN?
Our model-based fair value for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 5.23 TRY (as of Sep 13, 2026), built from audited fundamentals. The current price: 7.72 TRY.
What is the quality score of ANGEN?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Our model-based price target is the fair value of 5.23 TRY (as of Sep 13, 2026) from 2 valuation models. Cautious scenario 3.73 TRY, optimistic scenario 6.74 TRY. It is a calculation from audited fundamentals, not an analyst target.
What is the Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock forecast for 2026?
Our models put fair value at 5.23 TRY, about −32% upside versus a price of 7.72 TRY (overvalued). Cautious scenario 3.73 TRY, optimistic scenario 6.74 TRY. The calculation is refreshed regularly with new filings.
What is the revenue of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret reported trailing-twelve-month revenue of about 788M TRY (latest available figure, as of Sep 13, 2026).
Does Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret pay a dividend?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret currently shows a dividend yield of about 12.95% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret it is 5.23 TRY per share (as of Sep 13, 2026), against a price of 7.72 TRY. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock overvalued or undervalued in 2026?
As of Sep 13, 2026, ANGEN trades above its calculated fair value: price 7.72 TRY, fair value 5.23 TRY, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ANGEN?
No. The price is what the market pays today (7.72 TRY); the fair value is what the company's own numbers justify (5.23 TRY). For Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret the two are 2.49 TRY per share apart. That gap is exactly why we show both numbers side by side.
How much is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret worth?
The market values Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret at about 2.1B TRY (market capitalisation, as of Sep 13, 2026). Per share that is 7.72 TRY; our models calculate a fair value of 5.23 TRY per share.
What do the bullish and bearish scenarios say about ANGEN?
Our models span a range for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret: cautious scenario 3.73 TRY, base 5.23 TRY, optimistic 6.74 TRY per share (as of Sep 13, 2026, price 7.72 TRY). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Balance-sheet figures for Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (as of Sep 13, 2026): return on equity −16.4%, debt of 0.11 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is ANGEN from its 52-week high?
Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret trades at 7.72 TRY, about 52% below its 52-week high of 16.00 TRY (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 5.23 TRY is for.
Which stocks are comparable to Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret stock attractive at the current price?
The data as of Sep 13, 2026: price 7.72 TRY, calculated fair value 5.23 TRY (−32%), Quality Score 26/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ANGEN calculated?
We run Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5.23 TRY, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5 % above its aggregate fair value. Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The closing price on Sep 18, 2026 was 7.72 TRY. Our model-based fair value is 5.23 TRY, about −32% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret right now?
The price sits above even our optimistic bull case (6.74 TRY). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (3.73 TRY to 6.74 TRY) leaves room in how you read the outcome.
Key figures of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret
How large is the market capitalisation of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The market capitalisation of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 2.1B TRY (≈ $42.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The price-to-sales ratio of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 2.61 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Earnings per share at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret are −1.46 TRY. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The dividend yield of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 13.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The net margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −42.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The return on equity (ROE) of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −16.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
On an EBIT basis the return on assets of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
The operating margin of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 3.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Revenue at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is growing +19.1% versus a year earlier (3y avg +40.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN)?
Earnings per share at Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret are growing −93.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) generate?
The free cash flow of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is −186M TRY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) carry?
The net debt of Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret is 175M TRY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret in the live analysis
One click puts Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
